Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) - Phase 3 Study of Pembrolizumab with/without Epacadostat in UC

Incyte Corporation0 sites648 target enrollmentOctober 25, 2017

ConditionsRecurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864 Therapeutic area: Diseases [C] - Cancer [C04]

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease
Sponsor: Incyte Corporation
Enrollment: 648
Status: Active, not recruiting
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

October 25, 2017

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Incyte Corporation

Eligibility Criteria

Inclusion Criteria

•1\. Have histologically\-confirmed diagnosis of UC of the renal pelvis, ureter, bladder, or urethra, that is transitional cell, or mixed transitional/non\-transitional (predominantly transitional) cell type.
•2\. Have progression or recurrence of UC following one prior platinum containing chemotherapy regimen for metastatic or unresectable locally advanced disease. No additional lines of systemic treatment are allowed.
•3\. Have the presence of at least one measurable lesion by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1\.1 as determined by the investigator/local radiology assessment.
•a. If participants have only 1 measurable lesion per RECIST 1\.1, any biopsy specimen should be obtained from the non\-target lesion or archival tissue.
•b. If participants have only 1 measurable lesion per RECIST 1\.1, this lesion should not have been in the field of prior irradiation unless there is documented progression of the lesion(s).
•4\. Have provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated for PD\-L1 analysis. A newly obtained biopsy is strongly preferred but not required if archival tissue is adequate for analysis. If submitting unstained cut slides, freshly cut slides should be submitted to the central laboratory within 14 days from when the slides are cut. Refer to Section 9\.8\.1 in the protocol for an explanation. PD\-L1 status (CPS \=10 or CPS \<10\) must be determined by the central laboratory prior to randomization. Participants will be excluded if PD\-L1 status cannot be determined.
•5\. Have resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). Participants with \=Grade 2 neuropathy are an exception and may enroll.
•6\. Be \=18 years of age on day of signing informed consent.
•7\. Eastern Cooperative Oncology Group (ECOG) performance status of 0\-1 within 14 days prior to randomization.
•Male participants:

Exclusion Criteria

•1\. Has urothelial carcinoma that is suitable for local therapy with curative intent.
•2\. Has presence of a gastrointestinal condition that in the opinion of the Investigator may affect drug absorption.
•3\. Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure. Medically controlled arrhythmia stable on medication is permitted.
•4\. Has a history or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful. Screening corrected QT interval (QTc) interval \>480 msec is excluded (corrected by Fridericia formula or Bazett formula). In the event that a single QTc is \>480 milliseconds, the participant may enroll if the average QTc for the 3 ECGs is \<480 milliseconds.
•5\. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
•6\. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.
•7\. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
•8\. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging, (note that repeat imaging should be performed during the study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
•9\. Has severe hypersensitivity (\=Grade 3\) to study treatment (pembrolizumab and epacadostat) and/or any of its excipients.
•10\. Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.